ドライアイ症候群治療市場規模、シェア、成長分析、タイプ別、薬品別、製品別、剤形別、販売チャネル別、地域別 - 産業予測、2025-2032年

ドライアイ症候群治療の世界市場規模は2023年に70億7,000万米ドルと評価され、予測期間（2025～2032年）のCAGRは7.0%で、2024年の75億6,000万米ドルから2032年には130億米ドルに成長する見通しです。

ドライアイ症候群治療の世界市場は、有病率の上昇と高齢化によって力強い成長を遂げています。認知度の向上、診断ツールの技術的進歩、患者の快適性の重視が市場拡大を後押ししています。主な治療オプションは、人工涙液、抗炎症薬、免疫調節薬などの医薬品による介入です。さらに、ドライアイ症候群の根本原因への対処が期待される再生医療や遺伝子治療などの革新的な治療への動向も高まっています。研究開発が強化されるにつれて、市場は継続的な成長を遂げ、治療効果を高め、患者の予後を改善する態勢が整いつつあります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術分析
• 貿易分析

ドライアイ症候群治療市場規模：タイプ別

• 市場概要
• 蒸発性ドライアイ症候群
• 涙液減少性ドライアイ症候群

ドライアイ症候群治療市場規模：薬品別

• 市場概要
• シイドラ
• レスタシス
• セクア
• ティルヴァヤ
• エイスヴィス
• その他

ドライアイ症候群治療市場規模：製品別

• 市場概要
• 人工涙液
• シクロスポリン
• 局所コルチコステロイド
• 涙点プラグ
  • 取り外し可能
  • 溶解性
• 経口オメガサプリメント
• その他

ドライアイ症候群治療市場規模：剤形別

• 市場概要
• 点眼薬/溶液
• 軟膏とジェル
• カプセル・タブレット（サプリメント用）
• その他の剤形

ドライアイ症候群治療市場規模：販売チャネル別

• 市場概要
• 処方箋
• 店頭
• その他

ドライアイ症候群治療市場規模：流通チャネル別

• 市場概要
• 小売薬局
• 病院薬局
• オンライン薬局

ドライアイ症候群治療市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Novartis AG（Switzerland）
• AbbVie Inc.（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Santen Pharmaceutical Co. Ltd.（Japan）
• AFT Pharmaceuticals（New Zealand）
• Johnson & Johnson Services, Inc.（USA）
• Otsuka Pharmaceutical Co. Ltd.（Japan）
• OASIS Medical（USA）
• Bausch Health Companies Inc.（Canada）
• Alcon Inc.（Switzerland）
• Akorn Operating Company LLC（USA）
• Alimera Sciences（USA）
• GlaxoSmithKline plc（UK）
• Nicox S.A.（France）
• Novaliq GmbH（Germany）
• Horus Pharma（France）
• Mitotech（Russia）
• Prestige Consumer Healthcare（USA）
• Sentiss Pharma Pvt. Ltd.（India）
• VISUfarma（Netherlands）

結論と推奨事項

Global Dry Eye Syndrome Treatment Market size was valued at USD 7.07 billion in 2023 and is poised to grow from USD 7.56 billion in 2024 to USD 13.0 billion by 2032, growing at a CAGR of 7.0% during the forecast period (2025-2032).

The global dry eye syndrome treatment market is experiencing robust growth, driven by the rising prevalence of the condition and an aging population. Increased awareness, coupled with technological advancements in diagnostic tools, and a focus on patient comfort, are propelling market expansion. The primary treatment options remain pharmaceutical interventions, such as artificial tears, anti-inflammatory drugs, and immunomodulators. Additionally, there's a growing trend towards innovative therapies, including regenerative medicine and gene therapy, which hold promise for addressing the root causes of dry eye syndrome. As research and development efforts intensify, the market is poised for continued growth, enhancing treatment efficacy and improving patient outcomes in the years ahead.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dry Eye Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Dry Eye Syndrome Treatment Market Segmental Analysis

Global Dry Eye Syndrome Treatment Market is segmented by Type, Drugs, Product, Dosage Form, Sales Channel, Distribution Channel and region. Based on Type, the market is segmented into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on Drugs, the market is segmented into Xiidra, Restasis, Cequa, Tyrvaya, Eysuvis and Others. Based on Product, the market is segmented into Artificial Tears, Cyclosporine, Topical Corticosteroids, Punctal Plugs, Oral Omega Supplements and Others. Based on Dosage Form, the market is segmented into Eye Drops/ Solutions, Ointments and Gels, Capsules & Tablets (For Supplements) and Other Dosage Forms. Based on Sales Channel, the market is segmented into Prescription, OTC and Others. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Dry Eye Syndrome Treatment Market

The global dry eye syndrome treatment market is experiencing significant growth driven by several factors contributing to the rising incidence of dry eye syndrome (DES) worldwide. Increased screen time associated with digital technology usage, an aging population, environmental pollution, and changing lifestyles have all significantly heightened the occurrence of DES. Consequently, this has led to a surge in demand for effective and innovative treatment solutions such as artificial tears, anti-inflammatory medications, and punctal plugs. This growing awareness and need for advanced therapeutic options are crucial in facilitating the expansion of the dry eye syndrome treatment market on a global scale.

Restraints in the Global Dry Eye Syndrome Treatment Market

The global dry eye syndrome treatment market faces a significant challenge due to the absence of a universal treatment solution. This condition is multifaceted, with various underlying causes such as aqueous deficiency and evaporative dysfunction, which results in a wide disparity in treatment effectiveness among patients. This variability often leads to extensive trial and error for individuals, causing frustration and delays in achieving relief. Furthermore, the complexity of dry eye syndrome complicates the pharmaceutical industry's efforts to create new therapies tailored to the distinct needs of each patient, ultimately hindering the potential growth of the market.

Market Trends of the Global Dry Eye Syndrome Treatment Market

The Global Dry Eye Syndrome Treatment market is increasingly shifting towards preservative-free eye drops and artificial tears, driven by a heightened awareness of the adverse effects associated with conventional preservatives. This trend reflects a broader consumer demand for safer, more effective therapeutic options that minimize irritation and enhance comfort for patients suffering from this chronic condition. As a result, pharmaceutical companies are investing in the development of innovative preservative-free formulations, aligning with patient preferences and regulatory pushes for safer healthcare products. Additionally, this trend is bolstered by the rising incidence of dry eye syndrome due to lifestyle factors, creating a robust market opportunity.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis
• Trade Analysis

Global Dry Eye Syndrome Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Evaporative Dry Eye Syndrome
• Aqueous Deficient Dry Eye Syndrome

Global Dry Eye Syndrome Treatment Market Size by Drugs & CAGR (2025-2032)

• Market Overview
• Xiidra
• Restasis
• Cequa
• Tyrvaya
• Eysuvis
• Others

Global Dry Eye Syndrome Treatment Market Size by Product & CAGR (2025-2032)

• Market Overview
• Artificial Tears
• Cyclosporine
• Topical Corticosteroids
• Punctal Plugs
  • Removable
  • Dissolvable
• Oral Omega Supplements
• Others

Global Dry Eye Syndrome Treatment Market Size by Dosage Form & CAGR (2025-2032)

• Market Overview
• Eye Drops/ Solutions
• Ointments and Gels
• Capsules & Tablets (For Supplements)
• Other Dosage Forms

Global Dry Eye Syndrome Treatment Market Size by Sales Channel & CAGR (2025-2032)

• Market Overview
• Prescription
• OTC
• Others

Global Dry Eye Syndrome Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Dry Eye Syndrome Treatment Market Size & CAGR (2025-2032)

• North America (Type, Drugs, Product, Dosage Form, Sales Channel, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drugs, Product, Dosage Form, Sales Channel, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drugs, Product, Dosage Form, Sales Channel, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drugs, Product, Dosage Form, Sales Channel, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drugs, Product, Dosage Form, Sales Channel, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co. Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AFT Pharmaceuticals (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co. Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OASIS Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akorn Operating Company LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nicox S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novaliq GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horus Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitotech (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prestige Consumer Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sentiss Pharma Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VISUfarma (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations